Astellas Pharma Inc. (OTCPK:ALPMF) Q4 2024 Earnings Conference Call April 25, 2025 4:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IR Officer Naoki Okamura - Representative Director, President & Chief Executive Officer Claus Zieler - Chief Commercial Officer & Medical Affairs Officer Tadaaki Taniguchi - Chief Medical Officer Atsushi Kitamura - Chief Financial Officer Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Seiji Wakao - JPMorgan Securities Akinori Ueda - Goldman Sachs Securities Shinichiro Muraoka - Morgan Stanley MUFG Securities Hiroyuki Matsubara - Nomura Securities Miki Sogi - Sanford C. Bernstein Kazuaki Hashiguchi - Daiwa Securities Fumiyoshi Sakai - UBS Securities Hiromitsu Ikeda Thank you very much for joining our FY 2024 Financial Results Announcement Meeting by Astellas Pharma Inc. out of your very busy schedule today.
Astellas Pharma Inc. has a diverse pipeline with significant growth in oncology, driven by new approvals for drugs like zolbetuximab. Despite recent stock declines, ALPMF's revenue and core profits have grown, supported by strong sales of enzalutamide and faster-than-expected zolbetuximab market penetration. Operational expenses have increased due to amortization and terminated projects, impacting operating profit, but new product launches and approvals indicate potential for future growth.
Astellas Pharma Inc. (OTCPK:ALPMF) Q3 2024 Earnings Conference Call February 4, 2025 2:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IR Officer Atsushi Kitamura - Chief Financial Officer Tadaaki Taniguchi - Chief Medical Officer Claus Zieler - Chief Commercial Officer Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Seiji Wakao - JPMorgan Securities Shinichiro Muraoka - Morgan Stanley MUFG Securities Akinori Ueda - Goldman Sachs Securities Hiroyuki Matsubara - Nomura Securities Shinichiro Hyogo - Mitsubishi UFJ Trust Bank Miki Sogi - Sanford C. Berstein Fumiyoshi Sakai - UBS Securities Kazuaki Hashiguchi - Daiwa Securities Hiromitsu Ikeda Thank you very much for your attendance on to this Q3 Y-to-D FY '24 Financial Results Announcement Meeting.
![]() ALPMF In 8 months | Other | $0.27 Per Share |
![]() ALPMF In 2 months | Other | $0.27 Per Share |
![]() ALPMF 3 months ago Paid | Other | $0.25 Per Share |
![]() ALPMF 9 months ago Paid | Other | $0.24 Per Share |
![]() ALPMF 9 months ago | Other | $0.26 Per Share |
31 Jul 2025 (In 3 weeks) Date | | 10.2 Cons. EPS | - EPS |
29 Jul 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
23 Apr 2025 Date | | - Cons. EPS | - EPS |
2 Feb 2025 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | 22.6 Cons. EPS | 20.06 EPS |
![]() ALPMF In 8 months | Other | $0.27 Per Share |
![]() ALPMF In 2 months | Other | $0.27 Per Share |
![]() ALPMF 3 months ago Paid | Other | $0.25 Per Share |
![]() ALPMF 9 months ago Paid | Other | $0.24 Per Share |
![]() ALPMF 9 months ago | Other | $0.26 Per Share |
31 Jul 2025 (In 3 weeks) Date | | 10.2 Cons. EPS | - EPS |
29 Jul 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
23 Apr 2025 Date | | - Cons. EPS | - EPS |
2 Feb 2025 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | 22.6 Cons. EPS | 20.06 EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Mr. Naoki Okamura BSc CEO | OTC PINK Exchange | JP3942400007 ISIN |
JP Country | 14,754 Employees | 31 Mar 2026 Last Dividend | 27 Mar 2014 Last Split | - IPO Date |
Astellas Pharma Inc. is a distinguished player in the pharmaceutical industry operating not only domestically in Japan but also on an international scale. Founded in 1923 and with its headquarters nestled in Tokyo, Japan, the company has carved a niche for itself through the manufacturing, marketing, importing, and exporting of pharmaceuticals. Astellas's dedication to advancing medical care is proven through its consistent efforts in research and development, which has led to valuable collaborations. Notably, the company has formed a research collaboration with Vivtex Corporation to assess the potential of Vivtex's GI-ORIS screening and formulation technology. This partnership aims to enhance the oral delivery mechanisms of therapeutic candidates offered by Astellas. Additionally, a significant partnership with Roche Diabetes Care Japan Co., Ltd. showcases Astellas's commitment toward advancing diabetes care through the development and commercialization of an integrated diabetes self-management solution, cementing its role as an innovation-driven pharmaceutical powerhouse.